1 strategies for vaccinating children against
novel influenza A (H1N1) as well as seasonal influenza.
2 recent evidence, particularly after the 2009
novel influenza A (H1N1) pandemic, is limited.
3 A large outbreak of
novel influenza A (H1N1) virus (swine origin influenza v
4 In the spring of 2009, a
novel influenza A (H1N1) virus (swine origin influenza v
5 This recent outbreak of infection with a
novel influenza A (H1N1) virus also demonstrates the imp
6 In the spring of 2009, a
novel influenza A (H1N1) virus emerged in North America
7 A
novel influenza A (H1N1) virus has spread rapidly across
8 atory during a springtime 2009 outbreak of a
novel influenza A (H1N1) virus in New York State is desc
9 us on GBS when monovalent vaccines against a
novel influenza A (H1N1) virus of swine origin were intr
10 Given the current worldwide threat of
novel influenza A (H1N1), with an estimated R of 1.4-1.6
11 In 2009, a
novel influenza A (pH1N1) was identified, resulting in a
12 The emergence of
novel influenza A H1N1 and highly pathogenic avian influ
13 and recommendations for vaccination against
novel influenza A have emerged as well.
14 virus host factor that may be targeted as a
novel influenza A therapeutic strategy.
15 We report the isolation of a
novel influenza A virus (H2N2) cultured in 2013 from a h
16 The emergence of the
novel influenza A virus (IAV) H7N9 since 2013 has caused
17 In 2017, a
novel influenza A virus (IAV) was isolated from an Egypt
18 hat poor performance in the detection of the
novel influenza A virus 2009 H1N1 should preclude their
19 ed data on use of antivirals for humans with
novel influenza A virus infections of avian [A(H5N1), A(
20 nt and antiviral postexposure prophylaxis of
novel influenza A virus infections, discuss consideratio
21 recommendations on the use of antivirals for
novel influenza A virus infections.
22 or treatment and postexposure prophylaxis of
novel influenza A virus infections.
23 , understanding how orthomyxoviruses such as
novel influenza A virus reassortants and/or mutants emer
24 provide partial protection to humans against
novel influenza A virus strains introduced into humans f
25 efficiently among humans are essential for a
novel influenza A virus to cause a pandemic.
26 Two
novel influenza A virus-like genomes were detected in fr
27 ivated, do not protect against antigenically
novel influenza A viruses (IAVs) of pandemic potential,
28 Human infections with
novel influenza A viruses are of global public health co
29 zoonotic influenza in individuals exposed to
novel influenza A viruses associated with severe disease
30 tomatic zoonotic influenza after exposure to
novel influenza A viruses associated with severe disease
31 re chemoprophylaxis of human infections with
novel influenza A viruses associated with severe human i
32 tly been challenged by the identification of
novel influenza A viruses in bats(1,2).
33 Sporadic zoonotic infections with
novel influenza A viruses of avian or swine origin conti
34 Novel influenza A viruses of the H7N9 subtype [A(H7N9)]
35 The
novel influenza A viruses of the H7N9 subtype [A(H7N9)],
36 f influenza and monitor for the emergence of
novel influenza A viruses.
37 and have infected humans, are referred to as
novel influenza A viruses.
38 The 2009
novel influenza A(H1N1) pandemic period was excluded fro
39 In March 2013, a
novel influenza A(H7N9) virus emerged in China as an une
40 Two
novel influenza A-like viral genome sequences have recen
41 In this report, we used a
novel Influenza A/California/04/09 (H1N1) reporter virus
42 data available describing human immunity to
novel influenza A/H7N9.
43 phere winter of 2003-2004 the emergence of a
novel influenza antigenic variant, A/Fujian/411/2002-lik
44 Novel influenza antivirals are required, given limitatio
45 does this work describe the development of a
novel influenza assay, it also demonstrates the power of
46 We propose that the recent expansion of a
novel influenza B/Victoria clade may be associated with
47 ss-species transmission and pathogenicity of
novel influenza D viruses.
48 In the search for
novel influenza inhibitors we evaluated 7-fluoro-substit
49 tion options should initial containment of a
novel influenza outbreak fail, using Great Britain and t
50 Because of the continuous threat of
novel influenza outbreaks, it is essential to gather fur
51 as a first line of defense in the event of a
novel influenza pandemic.
52 ntervention policy during potentially severe
novel influenza pandemics.
53 xcluded from most clinical trials evaluating
novel influenza preventive and therapeutic strategies.
54 Following the detection of a
novel influenza strain A(H7N9), we modeled the use of an
55 Humans, upon infection with a
novel influenza strain, produce Abs against older viral
56 rrectly identify both well-characterized and
novel influenza strains offers the possibility to integr
57 In the context of recently emerged
novel influenza strains through reassortment, avian infl
58 e valid predictions of pandemic potential of
novel influenza strains, though results should continue
59 ts in studying the transmission potential of
novel influenza strains.
60 ody produced in response to vaccines against
novel influenza strains.
61 In theory, a similar
novel influenza subtype could be controlled.
62 In the pig, genetic reassortment to create
novel influenza subtypes by mixing avian, human, and swi
63 are few in-depth immunogenicity analyses of
novel influenza vaccination strategies in high-risk pati
64 ccur in coincident temporal association with
novel influenza vaccination.
65 The
novel influenza vaccine candidate, M2-deficient single r
66 Various
novel influenza vaccine candidates are being evaluated i
67 The
novel influenza vaccine MVA-NP+M1 is designed to boost c
68 In 2009, a
novel influenza vaccine was distributed worldwide to com
69 replication-incompetent NS2-knockout VLPs as
novel influenza vaccines and perhaps also as vectors to
70 n genes offers the possibility of developing
novel influenza vaccines and the feasibility for using r
71 lly catastrophic influenza pandemic requires
novel influenza vaccines that are safe, can be produced
72 ude timeliness and lower cost, but uptake of
novel influenza vaccines that is low and variable by age
73 Direct comparisons of similar doses of a
novel influenza virus antigen administered by the intrad
74 The frequency of
novel influenza virus detection is increasing, and human
75 nd transmission of and approaches to prevent
novel influenza virus infections.
76 The potential for
novel influenza virus lineages to evolve within Africa w
77 A-315675 is a
novel influenza virus NA inhibitor that has potent enzym
78 rge-scale sequencing effort, we identified a
novel influenza virus of wholly human origin that has be
79 Over the past 2 decades, several
novel influenza virus proteins have been identified that
80 asurement used for identifying antigenically
novel influenza virus strains.
81 Influenza D virus (FLUDV) is a
novel influenza virus that infects cattle and swine.
82 provide improved protection from infection,
novel influenza virus vaccines that target the conserved
83 increase the chances for the emergence of a
novel influenza virus with pandemic potential.
84 A
novel influenza virus, tentatively classified as influen
85 ldren are susceptible to infection with this
novel influenza virus.
86 gations for future pandemics or outbreaks of
novel influenza viruses among humans.
87 other respiratory pathogens will help detect
novel influenza viruses and inform and develop targeted
88 Influenza pandemics arise when
novel influenza viruses are introduced into a population
89 eems wise to conduct better surveillance for
novel influenza viruses at Chinese live bird markets.
90 ual circulation of seasonal influenza, while
novel influenza viruses invade the human population to c
91 blic health threat posed by the emergence of
novel influenza viruses necessitates the ability to rapi
92 The emergence of
novel influenza viruses that cause devastating human dis
93 to monitor H7N9 and detect other unexpected
novel influenza viruses that may emerge.
94 The genesis of
novel influenza viruses through reassortment poses a con
95 e influenza A viruses (swIAVs) in generating
novel influenza viruses with pandemic potential.
96 ant parameter in evaluating the virulence of
novel influenza viruses, and findings are extrapolated t
97 e future surveillance and risk assessment of
novel influenza viruses.
98 ddress humans as hosts for the generation of
novel influenza viruses.
99 in-specific or cross-protective vaccines for
novel influenza viruses.
100 dren are highly vulnerable to infection with
novel influenza viruses.
101 says commonly used to identify antigenically
novel influenza viruses.